Deregulation of New Cell Death Mechanisms in Leukemia

Gregorio Favale,Federica Donnarumma,Vincenza Capone,Laura Della Torre,Antonio Beato,Daniela Carannante,Giulia Verrilli,Asmat Nawaz,Francesco Grimaldi,Maria Carla De Simone,Nunzio Del Gaudio,Wouter Leonard Megchelenbrink,Michele Caraglia,Rosaria Benedetti,Lucia Altucci,Vincenzo Carafa

DOI: https://doi.org/10.3390/cancers16091657

2024-04-26

Cancers

Abstract:Hematological malignancies are among the top five most frequent forms of cancer in developed countries worldwide. Although the new therapeutic approaches have improved the quality and the life expectancy of patients, the high rate of recurrence and drug resistance are the main issues for counteracting blood disorders. Chemotherapy-resistant leukemic clones activate molecular processes for biological survival, preventing the activation of regulated cell death pathways, leading to cancer progression. In the past decade, leukemia research has predominantly centered around modulating the well-established processes of apoptosis (type I cell death) and autophagy (type II cell death). However, the development of therapy resistance and the adaptive nature of leukemic clones have rendered targeting these cell death pathways ineffective. The identification of novel cell death mechanisms, as categorized by the Nomenclature Committee on Cell Death (NCCD), has provided researchers with new tools to overcome survival mechanisms and activate alternative molecular pathways. This review aims to synthesize information on these recently discovered RCD mechanisms in the major types of leukemia, providing researchers with a comprehensive overview of cell death and its modulation.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the resistance of leukemia cells to cell death mechanisms, which leads to difficulties in treatment and the emergence of drug resistance. Specifically, the paper explores new regulated cell death (RCD) processes and their dysregulated molecular mechanisms in different types of leukemia. In addition, the paper also discusses known or newly identified drug strategies that can regulate specific RCD mechanisms, thereby overcoming the survival mechanisms of leukemia cells and activating alternative molecular pathways to improve treatment efficacy.

The key points of the paper are:
1. **Identifying new cell death mechanisms**: According to the classification of the Nomenclature Committee on Cell Death (NCCD), the paper introduces newly discovered RCD mechanisms that may become new tools for overcoming the survival mechanisms of leukemia cells.
2. **Molecular basis of drug resistance**: The paper details how leukemia cells evade cell death by activating specific molecular pathways, thereby leading to the emergence of drug resistance.
3. **Potential therapeutic targets**: The paper summarizes the key biomarkers of multiple RCD mechanisms, which may be potential drug targets for overcoming cell death resistance.
4. **Combination of immunotherapy**: The paper discusses how to enhance the ability of the immune system to eliminate leukemia cells through methods such as inducing immunogenic cell death (ICD).

Overall, this paper aims to provide researchers with a comprehensive perspective on new cell death mechanisms in leukemia and their potential for application in treatment.